News

Video

Updated Safety and Efficacy Data From the Phase 3 MANIFEST-2 Study of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients With Myelofibrosis

Author(s):

John Mascarenhas, MD

This is safety and efficacy update on the MANIFEST-2 trial (NCT02158858), a global, randomized, double-blind, active-control, phase 3 study using pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.

Related Videos
DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM)
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study
Intracranial Efficacy of Datopotamab Deruxtecan in Patients with Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer with Actionable Genomic Alterations: Results from Tropion-Lung05
Mikkael A. Sekeres, MD
Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: primary results from DESTINY-Breast06
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study
Ponatinib in patients with chronic-phase chronic myeloid leukemia and the T315I mutation: 4-year results from OPTIC
Related Content
Nina Mojas, senior vice president of Oncology Global Product Strategy at GlaxoSmithKline
June 24th 2024

Momelotinib Wins Japanese Approval for Myelofibrosis

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Michael Grunwald, MD, of Atrium Health
June 14th 2024

Observational Study Finds Progression Common in Lower-Risk Myelofibrosis

Courtney D. DiNardo, MD, MSCE
November 20th 2023

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

The FDA has approved imetelstat (Rytelo) for adults with low- to intermediate-1–risk myelodysplastic syndrome (MDS) and transfusion-dependent anemia requiring four or more red blood cell units over 8 weeks who have not responded to or have lost response to or are not eligible for erythropoiesis-stimulating agents.
June 7th 2024

FDA Approves Imetelstat for Low- to Intermediate-1–Risk MDS With Transfusion-Dependent Anemia

Raajit K. Rampal, MD, PhD
June 1st 2024

Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis